About OctreoPharm Sciences GmbH

About OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH (OPS), located at the Biomedical Research Campus in Berlin-Buch (Germany), is a privately held clinical development biopharmaceutical company (founded in 2010) focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors.



Radiopharmaceuticals are medicinal formulations containing radioisotopes, which are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases, i.e. cancer.

The term radioisotope has historically been used to refer to all radiopharmaceuticals, and this usage remains common. Technically, however, many radiopharmaceuticals incorporate a radioactive tracer atom into a larger pharmaceutically-active molecule, which is localized in the body, after which the radionuclide tracer atom allows it to be easily detected with an imaging device, i.e. Gamma Camera or PET/CT.

The use of specific radiopharmaceuticals for imaging of organ function and disease states is a unique capability of nuclear medicine. Unlike other imaging modalities such as CT, MRI and Ultrasonography, nuclear medicine procedures are capable of mapping physiological function and metabolic activity and thereby giving more specific information about the organ function and dysfunction.

New oncology products like OPS201 and OPS202 are being developed for diagnose, staging and monitoring of cellular response and for tumor-cell selective internal radiation therapy in a Theranostics, personalized approach.


INNOVATIVE THROUGH RESEARCH awarded by the Stifterverband

OctreoPharm Sciences‘ research activities are honored by the Stifterverband für die Deutsche Wissenschaft with the quality seal “Innovative through research”.